|
KMID : 1007420120100010005
|
|
Mood and Emotion
2012 Volume.10 No. 1 p.5 ~ p.12
|
|
|
Clinical Efficacy of the Novel Antidepressant Agomelatine
|
|
Woo Young-Sup
Bahk Won-Myong
|
|
|
Abstract
|
|
|
|
Major depression is highly prevalent mental illness and one of the leading causes of premature death and disability. Although current available pharmacological agents are recognized to be effective, delayed onset of action, partial or total resistance to drug treatment and distressing side effects have leaded to continued search for novel antidepressant. Recent understandings of the fundamental links between major depression and disturbed circadian rhythms have led to a renewed focus on this area. Agomelatine is a new agent with a unique pharmacological profile, melatonin receptor agonist and selective antagonist at 5HT2C receptors. Many clinical trials have demonstrated the superior antidepressant efficacy of agomelatine in comparison with placebo in the treatment major depression and similar antidepressant efficacy to venlafaxine, fluoxetine and sertraline. Agomelatine was even effective in severely depressed patients. Agomelatine has less potential for the side effects including serotonin syndrome and sexual dysfunction or discontinuation syndrome than typical to other therapies, such as selective serotonin reuptake inhibitors. These properties give agomelatine a definite clinical advantage in the treatment of depression.
|
|
|
KEYWORD
|
|
|
Agomelatine, Major depression, Efficacy, Safety
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|